- Home
- NWN vs NVCR Comparison
NWN vs NVCR Comparison
Compare NWN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWN
- NVCR
- Stock Information
- Founded
- NWN 1859
- NVCR 2000
- Country
- NWN United States
- NVCR Switzerland
- Employees
- NWN N/A
- NVCR N/A
- Industry
- NWN Oil/Gas Transmission
- NVCR Medical/Dental Instruments
- Sector
- NWN Utilities
- NVCR Health Care
- Exchange
- NWN Nasdaq
- NVCR Nasdaq
- Market Cap
- NWN 1.6B
- NVCR 1.4B
- IPO Year
- NWN N/A
- NVCR 2015
- Fundamental
- Price
- NWN $41.84
- NVCR $12.28
- Analyst Decision
- NWN Buy
- NVCR Buy
- Analyst Count
- NWN 2
- NVCR 7
- Target Price
- NWN $48.00
- NVCR $28.79
- AVG Volume (30 Days)
- NWN 239.0K
- NVCR 1.3M
- Earning Date
- NWN 08-05-2025
- NVCR 10-29-2025
- Dividend Yield
- NWN 4.69%
- NVCR N/A
- EPS Growth
- NWN 17.48
- NVCR N/A
- EPS
- NWN 2.58
- NVCR N/A
- Revenue
- NWN $1,238,288,000.00
- NVCR $630,160,000.00
- Revenue This Year
- NWN $17.95
- NVCR $6.68
- Revenue Next Year
- NWN $5.66
- NVCR $7.01
- P/E Ratio
- NWN $16.22
- NVCR N/A
- Revenue Growth
- NWN 8.40
- NVCR 14.58
- 52 Week Low
- NWN $38.03
- NVCR $10.87
- 52 Week High
- NWN $44.38
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- NWN 58.67
- NVCR 48.06
- Support Level
- NWN $40.98
- NVCR $11.71
- Resistance Level
- NWN $41.69
- NVCR $12.50
- Average True Range (ATR)
- NWN 0.59
- NVCR 0.45
- MACD
- NWN 0.08
- NVCR 0.20
- Stochastic Oscillator
- NWN 85.67
- NVCR 77.25
About NWN Northwest Natural Holding Company
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in one reportable business segment, which is NW Natural's local gas distribution business and is referred to as the NGD segment. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.